Belgium
CryoTherapeutics SA, founded in 2009 and headquartered in Belgium, is a pioneering company in the Biotechnology and Health Care sectors. The company focuses on a novel solution to stabilize vulnerable plaque and reduce heart attack risks using its unique cryotherapy system. This innovative approach addresses the unmet need for treating coronary vulnerable plaque, a primary cause of myocardial infarction, by applying localized cryotherapy directly to the plaques. Unlike traditional methods, CryoTherapeutics’ system provides a non-invasive alternative without foreign implants or reliance on prolonged medical therapy.
Their technology is currently in the clinical study phase and awaiting approval. Recently, CryoTherapeutics secured an €8.00 million debt financing investment from a consortium of investors, including KfW, Noshaq, NRW BANK, Peppermint Venture Partners, InnoMed Capital, Yellowstone Holding, and Buenavista Equity Partners. This substantial backing demonstrates strong investor confidence in their potential to revolutionize cardiac care.
